RU2017106891A - Биомаркеры поликистозной болезни почек и пути их применения - Google Patents
Биомаркеры поликистозной болезни почек и пути их применения Download PDFInfo
- Publication number
- RU2017106891A RU2017106891A RU2017106891A RU2017106891A RU2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A RU 2017106891 A RU2017106891 A RU 2017106891A
- Authority
- RU
- Russia
- Prior art keywords
- pkd
- patient
- protein
- cyclin
- kinase
- Prior art date
Links
- 208000030761 polycystic kidney disease Diseases 0.000 title claims 39
- 239000000090 biomarker Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 27
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 18
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims 18
- 108050006400 Cyclin Proteins 0.000 claims 17
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 17
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 17
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims 17
- 102000003861 Ribosomal protein S6 Human genes 0.000 claims 13
- 108090000221 Ribosomal protein S6 Proteins 0.000 claims 13
- 108091008611 Protein Kinase B Proteins 0.000 claims 12
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims 12
- 108010058546 Cyclin D1 Proteins 0.000 claims 11
- 108010058545 Cyclin D3 Proteins 0.000 claims 11
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims 11
- 102100037859 G1/S-specific cyclin-D3 Human genes 0.000 claims 11
- -1 5-fluoro-4- (4 - ((2-methoxyethoxy) methyl) phenyl) pyrimidin-2-yl Chemical group 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 102000011260 Retinoblastoma Binding Proteins Human genes 0.000 claims 7
- 108010023377 Retinoblastoma Binding Proteins Proteins 0.000 claims 7
- 102000004046 Caspase-2 Human genes 0.000 claims 6
- 108090000552 Caspase-2 Proteins 0.000 claims 6
- 239000013060 biological fluid Substances 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 6
- 108091005981 phosphorylated proteins Proteins 0.000 claims 6
- 201000000582 Retinoblastoma Diseases 0.000 claims 5
- 229940125921 glucosylceramide synthase inhibitor Drugs 0.000 claims 5
- 239000003892 ceramide glucosyltransferase inhibitor Substances 0.000 claims 4
- 210000001808 exosome Anatomy 0.000 claims 4
- 210000002700 urine Anatomy 0.000 claims 4
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- UMWIMNNPYBWNRY-XMMPIXPASA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[4-[4-(2-methoxyethoxy)phenyl]phenyl]propan-2-yl]carbamate Chemical compound C1=CC(OCCOC)=CC=C1C1=CC=C(C(C)(C)NC(=O)O[C@H]2C3CCN(CC3)C2)C=C1 UMWIMNNPYBWNRY-XMMPIXPASA-N 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033031P | 2014-08-04 | 2014-08-04 | |
| US62/033,031 | 2014-08-04 | ||
| PCT/US2015/043497 WO2016022500A2 (en) | 2014-08-04 | 2015-08-03 | Biomarkers of polycystic kidney disease and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017106891A true RU2017106891A (ru) | 2018-09-06 |
| RU2017106891A3 RU2017106891A3 (enExample) | 2019-03-14 |
Family
ID=54035292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106891A RU2017106891A (ru) | 2014-08-04 | 2015-08-03 | Биомаркеры поликистозной болезни почек и пути их применения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10871495B2 (enExample) |
| EP (1) | EP3177932B1 (enExample) |
| JP (2) | JP6730252B2 (enExample) |
| KR (1) | KR20170033436A (enExample) |
| CN (1) | CN106716136B (enExample) |
| AU (1) | AU2015301278A1 (enExample) |
| BR (1) | BR112017002003A2 (enExample) |
| CO (1) | CO2017001596A2 (enExample) |
| MX (1) | MX2017001648A (enExample) |
| RU (1) | RU2017106891A (enExample) |
| SG (1) | SG11201700290SA (enExample) |
| WO (1) | WO2016022500A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116755B2 (en) | 2015-11-18 | 2021-09-14 | Genzyme Corporation | Biomarker of polycystic kidney disease and uses thereof |
| GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
| KR102859441B1 (ko) * | 2019-11-22 | 2025-09-12 | 서울대학교산학협력단 | Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003500418A (ja) * | 1999-05-24 | 2003-01-07 | エイブイアイ バイオファーマ， インコーポレイテッド | 多発性嚢胞腎疾患の処置のためのｃ−ｍｙｃに対するアンチセンス |
| US9006181B2 (en) | 2004-07-21 | 2015-04-14 | The Administrators Of The Tulane Educational Fund | Treatment of renal dysfunction and multiple myeloma using PACAP compounds |
| EP1808694A1 (en) | 2006-01-17 | 2007-07-18 | Universitätsklinikum Freiburg | Method for diagnosing polycystic kidney disease |
| US20120077263A1 (en) | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
| CN102018702B (zh) * | 2009-09-16 | 2012-07-18 | 北京大学 | 银杏内酯b的一种用途 |
| US20140079769A1 (en) * | 2010-10-01 | 2014-03-20 | Fabiola Terzi | Methods for predicting the progression and treating a chronic kidney disease in a patient |
| US20130276513A1 (en) * | 2010-10-14 | 2013-10-24 | The Regents Of The University Of California | Methods for diagnosing and assessing kidney disease |
| ES2982997T3 (es) | 2012-07-03 | 2024-10-21 | Fond Centro San Raffaele | 2-desoxiglucosa para uso en el tratamiento de la enfermedad renal poliquística dominante autosomal o enfermedad hepática poliquística |
| JOP20130273B1 (ar) | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
-
2015
- 2015-08-03 JP JP2017506291A patent/JP6730252B2/ja active Active
- 2015-08-03 AU AU2015301278A patent/AU2015301278A1/en not_active Abandoned
- 2015-08-03 SG SG11201700290SA patent/SG11201700290SA/en unknown
- 2015-08-03 BR BR112017002003A patent/BR112017002003A2/pt not_active Application Discontinuation
- 2015-08-03 WO PCT/US2015/043497 patent/WO2016022500A2/en not_active Ceased
- 2015-08-03 RU RU2017106891A patent/RU2017106891A/ru not_active Application Discontinuation
- 2015-08-03 MX MX2017001648A patent/MX2017001648A/es unknown
- 2015-08-03 KR KR1020177005740A patent/KR20170033436A/ko not_active Withdrawn
- 2015-08-03 EP EP15757363.5A patent/EP3177932B1/en active Active
- 2015-08-03 US US15/501,496 patent/US10871495B2/en active Active
- 2015-08-03 CN CN201580053081.4A patent/CN106716136B/zh active Active
-
2017
- 2017-02-17 CO CONC2017/0001596A patent/CO2017001596A2/es unknown
-
2020
- 2020-07-01 JP JP2020113693A patent/JP7005695B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3177932A2 (en) | 2017-06-14 |
| JP2020170013A (ja) | 2020-10-15 |
| RU2017106891A3 (enExample) | 2019-03-14 |
| EP3177932B1 (en) | 2021-07-14 |
| JP6730252B2 (ja) | 2020-07-29 |
| JP7005695B2 (ja) | 2022-02-04 |
| CN106716136A (zh) | 2017-05-24 |
| BR112017002003A2 (pt) | 2017-12-12 |
| CN106716136B (zh) | 2020-06-23 |
| KR20170033436A (ko) | 2017-03-24 |
| US20170227551A1 (en) | 2017-08-10 |
| MX2017001648A (es) | 2017-04-27 |
| US10871495B2 (en) | 2020-12-22 |
| CO2017001596A2 (es) | 2017-05-19 |
| WO2016022500A3 (en) | 2016-04-07 |
| SG11201700290SA (en) | 2017-02-27 |
| WO2016022500A2 (en) | 2016-02-11 |
| JP2017525955A (ja) | 2017-09-07 |
| AU2015301278A1 (en) | 2017-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Mouse models of intracerebral hemorrhage in ventricle, cortex, and hippocampus by injections of autologous blood or collagenase | |
| Paulsson et al. | Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| Amajoyi et al. | Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens | |
| WO2015057968A3 (en) | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same | |
| RU2017106891A (ru) | Биомаркеры поликистозной болезни почек и пути их применения | |
| Karaman et al. | Factors affecting postoperative mortality in patients older than 65 years undergoing surgery for hip fracture | |
| EA201892542A1 (ru) | Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19 | |
| RU2012148816A (ru) | Метод диагностики для определения клеток ex vivo | |
| Fogelman et al. | Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? | |
| JP2016528914A5 (enExample) | ||
| BR112016014072A2 (pt) | anticorpo isolado, sintético ou recombinante humano, ou uma parte funcional ou um equivalente funcional do mesmo, molécula de ácido nucleico isolado, sintético ou recombinante, vetor, célula isolada ou recombinante ou um animal não humano, composição, uso de um anticorpo ou parte funcional ou equivalente funcional, e, métodos para produzir um anticorpo ou parte funcional ou equivalente funcional, para detectar células mieloproliferativas ou linfoproliferativas, para determinar se uma célula mieloide ou célula linfoide é uma célula mieloproliferativa ou célula linfoproliferativa, para identificar células mieloproliferativas ou linfoproliferativas, para determinar se células mieloproliferativas ou linfoproliferativas estão presentes em uma amostra, para tratar e/ou prevenir um distúrbio mieloproliferativo ou linfoproliferativo, para determinar se um indivíduo sofre de um distúrbio mieloproliferativo ou linfoproliferativo, para tipificar uma amostra contendo célula mieloide ou uma amostra contendo célula linfoide de um indivíduo, e, para determinar se um paciente que sofre de um distúrbio mieloproliferativo ou distúrbio linfoproliferativo é um candidato para o tratamento com um anticorpo | |
| Brown et al. | Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development | |
| JP2017525955A5 (enExample) | ||
| JP2019502902A5 (enExample) | ||
| Moskowitz et al. | Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no… well yes,… but maybe not for long | |
| Yanaba et al. | Increased circulating soluble vascular adhesion protein‐1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease | |
| EA201300410A1 (ru) | Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2 | |
| BR112015022579A2 (pt) | uso de shroom 3 em doença renal crônica e nefropatia crônica do aloenxerto | |
| Walmsley | Comment on an optimized patient-reported ulcerative colitis disease activity measure derived from the mayo score and the simple clinical colitis activity index | |
| Markopoulos | IMPACT OF THE 21-GENE RECURRENCE SCORE ASSAY ON TREATMENT DECISION IN EARLY BREAST CANCER (EBC) PATIENTS WITH FAVORABLE PROGNOSTIC FACTORS | |
| Bauzá et al. | The effects of injury magnitude on the kinetics of the acute phase response | |
| WEN et al. | Expressions of miR-17 and miR-20a in CD4+ T cells from patients with systemic lupus erythematosus and their correlations with disease activity | |
| Moody | Overcoming Resistance to Trastuzumab in HER2-Amplified Breast Cancers | |
| Osama S et al. | Characterization of cancer stem cells in patients with brain astrocytomas: a clinico-pathological and immunohistochemical study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190627 |